PECCI, FEDERICA
 Distribuzione geografica
Continente #
AS - Asia 831
NA - Nord America 245
EU - Europa 158
SA - Sud America 35
AF - Africa 12
Totale 1.281
Nazione #
SG - Singapore 277
CN - Cina 248
US - Stati Uniti d'America 241
VN - Vietnam 126
HK - Hong Kong 84
IT - Italia 52
KR - Corea 43
NL - Olanda 29
BR - Brasile 27
DE - Germania 27
IN - India 27
FI - Finlandia 12
JP - Giappone 9
AT - Austria 8
AR - Argentina 7
ID - Indonesia 7
CI - Costa d'Avorio 5
GB - Regno Unito 5
RU - Federazione Russa 5
BE - Belgio 4
MX - Messico 4
AE - Emirati Arabi Uniti 3
BD - Bangladesh 3
FR - Francia 3
IL - Israele 3
LT - Lituania 3
PL - Polonia 3
SC - Seychelles 3
BG - Bulgaria 2
ES - Italia 2
BY - Bielorussia 1
DZ - Algeria 1
EC - Ecuador 1
GA - Gabon 1
GR - Grecia 1
NG - Nigeria 1
SE - Svezia 1
TJ - Tagikistan 1
ZA - Sudafrica 1
Totale 1.281
Città #
Singapore 193
Hefei 114
Hong Kong 83
Ashburn 68
Santa Clara 44
Seoul 43
Ho Chi Minh City 35
Hanoi 31
Boardman 21
Beijing 20
Bologna 12
Helsinki 12
Bengaluru 11
Falkenstein 9
Nuremberg 9
Tokyo 9
Dallas 8
Hyderabad 8
Haiphong 7
Los Angeles 7
Redondo Beach 7
Buffalo 6
Jakarta 6
Orem 6
Abidjan 5
Da Nang 5
Frankfurt am Main 5
Modena 5
Guangzhou 4
Ha Long 4
Indianapolis 4
San Francisco 4
Tongling 4
Verona 4
Amsterdam 3
Biên Hòa 3
Brussels 3
Can Tho 3
Denver 3
Harbin 3
Mumbai 3
Munich 3
Pietrasanta 3
Quận Một 3
Quận Phú Nhuận 3
Salt Lake City 3
San Jose 3
Shanghai 3
São Paulo 3
Tel Aviv 3
Turin 3
Vienna 3
Warsaw 3
Bonate Sopra 2
Brooklyn 2
Bắc Giang 2
Bắc Ninh 2
Foshan 2
Hải Dương 2
Mexico City 2
Milan 2
New Delhi 2
New York 2
Ninh Bình 2
Pescara 2
Rome 2
Salerno 2
Seattle 2
Sofia 2
Taurianova 2
Thái Bình 2
Thái Nguyên 2
Tianjin 2
Vinh 2
Vĩnh Tường 2
Wuxi 2
Xi'an 2
Yubileyny 2
Algiers 1
Amparo 1
Aparecida 1
Aracaju 1
Araçatuba 1
Arezzo 1
Atlanta 1
Bandung 1
Baoding 1
Bexley 1
Brasília 1
Bình Dương Province 1
Cachoeiro de Itapemirim 1
Cagliari 1
Canoas 1
Catania 1
Caucaia 1
Changchun 1
Changsha 1
Changzhou 1
Chengdu 1
Chennai 1
Totale 942
Nome #
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors 139
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors 126
Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’: [ESMO Open Volume 7, Issue 2, April 2022, 100406] 103
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC 101
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer 95
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study 82
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 74
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer 65
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma 56
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer 55
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer 55
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 54
The gustave roussy immune (Grim)-score variation is an early-on-treatment biomarker of outcome in advanced non-small cell lung cancer (nsclc) patients treated with first-line pembrolizumab 53
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer 51
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions 50
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC 45
Non-small-cell lung cancer: how to manage EGFR-mutated disease 43
Title: Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer 39
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC 39
Totale 1.325
Categoria #
all - tutte 3.577
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.577


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/20236 0 0 0 0 0 0 0 0 2 2 0 2
2023/202434 0 1 1 2 1 2 2 13 2 4 1 5
2024/2025513 5 42 59 27 74 17 39 24 10 37 56 123
2025/2026772 234 155 116 114 99 54 0 0 0 0 0 0
Totale 1.325